Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.

Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.

Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.

Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.

Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.

Abstract: In one embodiment, a method includes accessing, from a data store of the communication network, user information associated with a first user of the communication network, identifying one or more entities associated with the communication network that are relevant to the first user based on the user information, and retrieving, for each identified entity, one or more content frames associated with the entity. The method includes ranking the one or more content frames based on the user information. The method also includes sending, to a client device of the first user, one or more of the content frames for display to the first user in ranked order, wherein each content frame is selectable by the first user to display the selected content frame in association with a particular content item for a specified period of time.

Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.

Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.

Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.

Abstract: The present invention provides devices and methods for use in the perfusion of organs and anatomical regions. In one aspect the present method provides a percutaneously deliverable device for supporting a vessel in a human or animal subject including means for supporting the vessel during delivery of a fluid thereto or collection of a fluid therefrom. In another aspect the invention provides a method for delivery or collection of a fluid to or from an organ or anatomical region in a human or animal subject, the method including the step of supporting a vessel associated with the organ or anatomical region. The devices and methods may be used to deliver, remove or recirculate a therapeutic agent to an organ or anatomical region.

Abstract: A method of delivering a medicament to a limb of a patient body includes isolating a circulatory system of the limb from a circulatory system of the patient body, wherein the limb circulatory system is substantially all limb arteries and substantially all limb veins located between an isolation region and an end of the limb. A perfusion catheter is inserted into a limb artery in an antegrade position, while a collection catheter is inserted into a limb vein in a retrograde position. The blood flow of the limb circulatory system is then circulated by collecting the blood flow with the collection catheter and delivering the blood flow with the perfusion catheter. A medicament is perfused into the limb circulatory system with the perfusion catheter.

Abstract: In one embodiment, a method includes accessing, from a data store of the communication network, user information associated with a first user of the communication network, identifying one or more entities associated with the communication network that are relevant to the first user based on the user information, and retrieving, for each identified entity, one or more content frames associated with the entity. The method includes ranking the one or more content frames based on the user information. The method also includes sending, to a client device of the first user, one or more of the content frames for display to the first user in ranked order, wherein each content frame is selectable by the first user to display the selected content frame in association with a particular content item for a specified period of time.

Abstract: A method of delivering a medicament to a limb of a patient body includes isolating a circulatory system of the limb from a circulatory system of the patient body, wherein the limb circulatory system is substantially all limb arteries and substantially all limb veins located between an isolation region and an end of the limb. A perfusion catheter is inserted into a limb artery in an antegrade position, while a collection catheter is inserted into a limb vein in a retrograde position. The blood flow of the limb circulatory system is then circulated by collecting the blood flow with the collection catheter and delivering the blood flow with the perfusion catheter. A medicament is perfused into the limb circulatory system with the perfusion catheter.

Abstract: The present invention provides devices and methods for use in the perfusion of organs and anatomical regions. In one aspect the present method provides a percutaneously deliverable device for supporting a vessel in a human or animal subject including means for supporting the vessel during delivery of a fluid thereto or collection of a fluid therefrom. In another aspect the invention provides a method for delivery or collection of a fluid to or from an organ or anatomical region in a human or animal subject, the method including the step of supporting a vessel associated with the organ or anatomical region. The devices and methods may be used to deliver, remove or recirculate a therapeutic agent to an organ or anatomical region.

Abstract: A method of delivering a medicament to a limb of a patient body includes isolating a circulatory system of the limb from a circulatory system of the patient body, wherein the limb circulatory system is substantially all limb arteries and substantially all limb veins located between an isolation region and an end of the limb. A perfusion catheter is inserted into a limb artery in an antegrade position, while a collection catheter is inserted into a limb vein in a retrograde position. The blood flow of the limb circulatory system is then circulated by collecting the blood flow with the collection catheter and delivering the blood flow with the perfusion catheter. A medicament is perfused into the limb circulatory system with the perfusion catheter.

Abstract: A method includes establishing an initial resistive force on a contrast fluid in a contrast delivery modulation component and injecting the contrast fluid into the patient with an injection syringe fluidly connected to the injection catheter and the contrast fluid inlet port of the contrast delivery modulation component. A contrast delivery measurement component is used to assess a total volume of the contrast fluid injected into the patient and a resistive force imparted upon the contrast fluid in the chamber.

Abstract: A method of delivering a medicament to a limb of a patient body includes isolating a circulatory system of the limb from a circulatory system of the patient body, wherein the limb circulatory system is substantially all limb arteries and substantially all limb veins located between an isolation region and an end of the limb. A perfusion catheter is inserted into a limb artery in an antegrade position, while a collection catheter is inserted into a limb vein in a retrograde position. The blood flow of the limb circulatory system is then circulated by collecting the blood flow with the collection catheter and delivering the blood flow with the perfusion catheter. A medicament is perfused into the limb circulatory system with the perfusion catheter.

Abstract: In a method for substantially isolating cardiac circulation from systemic circulation, flow between the coronary sinus and the right atrium is occluded. A venous collection device having a collection lumen and a support structure is located in the coronary sinus. The support structure is used to maintain patency of the coronary sinus during collection of fluid through the collection lumen. An artificial flow path is provided between the collection lumen and the one or more coronary arteries, thus isolating the cardiac circulation. According to the method, cardiac pumping for systemic circulation can be maintained during isolation of the cardiac circulation.

Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.

Abstract: The present invention provides devices and methods for use in the perfusion of organs and anatomical regions. In one aspect the present method provides a percutaneously deliverable device for supporting a vessel in a human or animal subject including means for supporting the vessel during delivery of a fluid thereto or collection of a fluid therefrom. In another aspect the invention provides a method for delivery or collection of a fluid to or from an organ or anatomical region in a human or animal subject, the method including the step of supporting a vessel associated with the organ or anatomical region. The devices and methods may be used to deliver, remove or recirculate a therapeutic agent to an organ or anatomical region.